Status:
COMPLETED
Oncologic Impact of Pancreatic Fistula
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
IRCCS San Raffaele
Cisanello University Hospital (Pisa, Italy)
Conditions:
PDAC of the Body and the Tail of the Pancreas
CR- POPF
Eligibility:
All Genders
18-85 years
Brief Summary
Clinically-relevant post-operative fistula is a major complication after DP, but it did not affect post-operative therapeutic path nor oncologic long-term outcomes. CR-POPF was not a predictive factor...
Detailed Description
POPF is the most common and feared complication after distal pancreatectomy (DP), increasing morbidity and mortality. Recent evidences suggest that POPF can also play a role in pancreatic cancer recur...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- patient with resectable pancreatic ductal adenocarcinoma (PDAC) of the body and the tail of the pancreas undergone surgery
- Exclusion criteria:
- metastatic diseases (including para-aortic lymph nodes involvement)
- PDAC arising from Intraductal Papillary Mucinous Neoplasms (IPMN)
- resection for premalignant lesions including high-grade Pancreatic Intraepithelial Neoplasia (PanIN) or adenocarcinoma in situ (Tis)
- histological diagnosis other than PDAC
- all R2 resections.
Exclusion
Key Trial Info
Start Date :
January 30 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2018
Estimated Enrollment :
382 Patients enrolled
Trial Details
Trial ID
NCT04348084
Start Date
January 30 2009
End Date
December 30 2018
Last Update
April 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uh Montpellier
Montpellier, France, 34295